Business ❯Pharmaceutical Industry ❯Market Competition ❯Stock Market
Novo Nordisk files for FDA approval of its oral anti-obesity medication, following Eli Lilly's phase III success with orforglipron, the first oral GLP-1 to achieve this milestone.
